Krishna Chatterjee is distinguished for his discoveries of genetic disorders of thyroid gland formation, regulation of hormone synthesis and hormone action, which have advanced fundamental knowledge of the thyroid axis.

He has identified dominant negative inhibition by defective nuclear hormone receptors as a common mechanism in Resistance to Thyroid Hormone and PPARg-mediated insulin resistance. He has shown how deficiency of human selenocysteine-containing proteins causes a multisystem disease, including disordered thyroid hormone metabolism. He seeks to translate such understanding into better diagnosis and therapy of both rare and common thyroid conditions.

Krishna is a researcher at the interface of basic science and clinical medicine. He has developed and leads Clinical Research Facilities at the University of Cambridge.